← Eichor
Study identifier: NCT06717022 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Condition: Mesothelin Positive Tumors  ·  Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhaseNA
Planned participants24
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical University Cancer Institute & HospitalTianjin, Tianjin Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06717022